The E2F4 Knockout MES-OV Polyclonal Cells consist of a heterogeneous population of MES-OV cells edited by CRISPR/Cas9 to disrupt the E2F4 gene, generating a polyclonal knockout model. This product provides a powerful tool for investigating the functional roles of E2F4 in transcriptional repression and cell cycle control within the context of human ovarian adenocarcinoma. The polyclonal format preserves the complexity of CRISPR-induced genetic heterogeneity, enabling robust assessment of gene function in a pooled-cell setting.
The MES-OV cell line is derived from a human ovarian carcinoma and serves as a widely used epithelial model of ovarian adenocarcinoma. These cells retain key features of ovarian cancer biology, including dysregulated cell cycle and oncogenic signaling pathways. MES-OV cells are suitable for studying tumor cell proliferation, apoptosis, and drug response, providing a relevant platform for ovarian cancer research.
E2F4 is a member of the E2F family of transcription factors and functions primarily as a transcriptional repressor. In quiescent cells, E2F4 forms repressor complexes with the pocket proteins p130 (RBL2) or p107 (RBL1) and the DP partners TFDP1/DP2. These complexes, together with histone deacetylase HDAC1 and chromatin remodelers such as SWI/SNF, bind to E2F-responsive promoters and silence genes required for S-phase entry, including CCNA2, CCNE1, CDC2, and MYBL2. Upstream regulation of E2F4 is mediated by cyclin-dependent kinase inhibitors, TGF-beta signaling, and growth factor pathways that modulate CDK activity. In the canonical Rb pathway, cyclin D?CCDK4/6 phosphorylation of pocket proteins releases E2F4-mediated repression, allowing cell cycle progression. Thus, E2F4 sits at the intersection of multiple tumor suppressor networks.
Disruption of E2F4 in MES-OV cells abrogates its repressive function, removing a critical brake on cell cycle entry. This is expected to alter the expression of downstream targets and may enhance proliferation, perturb differentiation, and sensitize or desensitize cells to therapeutic agents. In ovarian cancer, where Rb pathway deregulation is common, this polyclonal knockout model provides a unique tool to dissect the contribution of E2F4 to tumor maintenance and progression, and to explore its role in drug resistance mechanisms.
The E2F4 Knockout MES-OV Polyclonal Cells enable a wide range of experimental applications, including cell cycle profiling by flow cytometry, proliferation and colony formation assays, RT-qPCR analysis of E2F4 target genes, and drug sensitivity screening. They are particularly valuable for studying the interplay between E2F4-mediated repression and other signaling pathways such as TGF-beta and Wnt, and for identifying synthetic lethal interactions or novel therapeutic targets in ovarian cancer. For additional information or technical support, please contact Ascent Research.
